Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.

作者信息

Waheed Aiman, Gul Muhammad H, Wardak Abdul B, Raja Hafsa A A, Hussaini Helai

机构信息

Rawalpindi Medical College, Rawalpindi, Pakistan.

Hayatabad Medical Complex, Peshawar, Pakistan.

出版信息

Ann Med Surg (Lond). 2024 Sep 20;86(11):6386-6388. doi: 10.1097/MS9.0000000000002591. eCollection 2024 Nov.

DOI:10.1097/MS9.0000000000002591

PMID:39525706

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11543176/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4111/11543176/cfeea4ca8f3f/ms9-86-6386-g001.jpg

相似文献

Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.

Ann Med Surg (Lond). 2024 Sep 20;86(11):6386-6388. doi: 10.1097/MS9.0000000000002591. eCollection 2024 Nov.

Nogapendekin alfa Inbakicept: First Approval.

Drugs. 2024 Jul;84(7):867-874. doi: 10.1007/s40265-024-02060-1. Epub 2024 Jul 5.

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24.

IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.

Urol Pract. 2024 Mar;11(2):367-375. doi: 10.1097/UPJ.0000000000000517. Epub 2024 Jan 16.

In brief: Anktiva for bladder cancer.

Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-e106. doi: 10.58347/tml.2024.1705e.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.

Novel intravesical therapies and delivery systems for the management of bladder cancer.

Curr Opin Urol. 2025 Jan 1;35(1):19-27. doi: 10.1097/MOU.0000000000001232. Epub 2024 Oct 7.

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.

Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.

Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?

Curr Opin Urol. 2024 Nov 1;34(6):489-494. doi: 10.1097/MOU.0000000000001213. Epub 2024 Aug 19.

引用本文的文献

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.

Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):5077-5099. doi: 10.1007/s00210-025-04020-2. Epub 2025 Mar 31.

IL-15: from discovery to FDA approval.

J Hematol Oncol. 2025 Feb 18;18(1):19. doi: 10.1186/s13045-025-01664-8.

本文引用的文献

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.

Eur Urol. 2024 Jan;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016. Epub 2023 Oct 17.

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.

J Clin Oncol. 2023 Dec 10;41(35):5437-5447. doi: 10.1200/JCO.23.00307. Epub 2023 Oct 4.

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.

Int J Mol Sci. 2023 Aug 9;24(16):12596. doi: 10.3390/ijms241612596.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Nat Rev Cancer. 2019 Mar;19(3):133-150. doi: 10.1038/s41568-019-0116-x.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18.

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

J Clin Oncol. 2016 Jun 1;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797. Epub 2016 Mar 21.

The Fate of Primary Nonrefluxing Megaureter: A Prospective Outcome Analysis of the Rate of Urinary Tract Infections, Surgical Indications and Time to Resolution.

J Urol. 2016 Apr;195(4 Pt 2):1300-5. doi: 10.1016/j.juro.2015.11.049. Epub 2016 Feb 28.

Incidental Diagnosis of Giant Cell Tumor After Urachal Remnant Removal in a Thalassemic Child.

Urology. 2016 Apr;90:170-2. doi: 10.1016/j.urology.2016.01.005. Epub 2016 Jan 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr超能文献

Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr
超能文献